← All drugs
Drug · FAERS side-effect profile with label screen

Cetirizine Hydrochloride Tablets side effects: what 30,106 FDA adverse event reports show

Cetirizine Hydrochloride Tablets · Cetirizine Hydrochloride · 1,224 reaction terms · 523,463 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Brand names

Cetirizine Hydrochloride

openFDA label

Who reports

30,106 reports · 78% serious · 4,852 with death outcome · 79% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Perennial Allergic Rhinitis: Cetirizine hydrochloride is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in children 6 to 23 months of age. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing.

FDA label, Indications and Usage

What it is

Cetirizine is a member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.

PubChem CID 2678 (ChEBI)

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled (related wording) 2Likely indication confounding 1Lab value / disease marker 8Not in label — unassessed 29
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,184 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Swollen joint count increased1,9721,222.4
1,136.6–1,314.6ROR 1,308.0 · calibrated p 1e-18 ✓
438.2 EB05 422.2 · IC025 +8.6
3/3 methods agree
Lab value / disease markerserious n=1,971 · ♀ 100% (drug 79%) · 95% cliniciannot reported in cached trials
Monocyte chemotactic protein-1 increased221,161.2
585.0–2,304.9ROR 1,162.1 · calibrated p 5e-15 ✓
314.0 EB05 218.5 · IC025 +4.6
3/3 methods agree
Lab value / disease markerserious n=22 · ♀ 0% (drug 79%)not reported in cached trials
Anti-cyclic citrullinated peptide antibody3991,053.0
901.1–1,230.6ROR 1,067.2 · calibrated p 2e-17 ✓
407.9 EB05 375.4 · IC025 +7.9
3/3 methods agree
Lab value / disease markerserious n=399 · ♀ 100% (drug 79%) · 94% cliniciannot reported in cached trials
Anti-cyclic citrullinated peptide antibody positive4,1741,008.2
962.5–1,055.9ROR 1,170.2 · calibrated p 4e-18 ✓
408.1 EB05 397.8 · IC025 +8.6
3/3 methods agree
Lab value / disease markerserious PRR 302.3 · ♀ 100% (drug 79%) · 93% cliniciannot reported in cached trials
Rheumatic fever2,557999.8
941.8–1,061.3ROR 1,092.4 · calibrated p 9e-18 ✓
406.3 EB05 393.2 · IC025 +8.5
3/3 methods agree
Not in label — unassessedserious n=2,556 · ♀ 100% (drug 79%) · 95% cliniciannot reported in cached trials
Hepatic enzyme81975.1
695.0–1,368.2ROR 977.7 · calibrated p 2e-16 ✓
368.2 EB05 305.7 · IC025 +6.5
3/3 methods agree
Not in label — unassessedserious n=81 · ♀ 100% (drug 79%) · 100% cliniciannot reported in cached trials
Pemphigus6,940893.5
863.7–924.2ROR 1,160.8 · calibrated p 4e-18 ✓
388.3 EB05 380.7 · IC025 +8.5
3/3 methods agree
Not in label — unassessedserious PRR 287.3 · ♀ 100% (drug 79%) · 90% cliniciannot reported in cached trials
Deep vein thrombosis postoperative1,094891.6
815.5–974.7ROR 925.1 · calibrated p 7e-17 ✓
385.7 EB05 366.9 · IC025 +8.3
3/3 methods agree
Not in label — unassessedserious n=1,094 · ♀ 100% (drug 79%) · 95% cliniciannot reported in cached trials
Lupus vulgaris654861.4
768.1–965.9ROR 880.5 · calibrated p 1e-16 ✓
378.2 EB05 354.5 · IC025 +8.1
3/3 methods agree
Not in label — unassessedserious n=654 · ♀ 100% (drug 79%) · 95% cliniciannot reported in cached trials
Rheumatoid factor positive3,007767.6
729.6–807.6ROR 852.7 · calibrated p 2e-16 ✓
362.0 EB05 351.3 · IC025 +8.4
3/3 methods agree
Lab value / disease markerserious n=3,005 · ♀ 100% (drug 79%) · 94% cliniciannot reported in cached trials
Grip strength115692.2
534.4–896.7ROR 694.9 · calibrated p 4e-15 ✓
326.3 EB05 279.3 · IC025 +6.8
3/3 methods agree
Not in label — unassessedserious n=115 · ♀ 100% (drug 79%) · 100% cliniciannot reported in cached trials
Swollen joint count122691.9
538.2–889.4ROR 694.7 · calibrated p 4e-15 ✓
327.3 EB05 281.4 · IC025 +6.9
3/3 methods agree
Not in label — unassessedserious n=122 · ♀ 100% (drug 79%) · 100% cliniciannot reported in cached trials
C-reactive protein449689.3
605.0–785.3ROR 699.7 · calibrated p 2e-15 ✓
339.4 EB05 313.8 · IC025 +7.8
3/3 methods agree
Lab value / disease markerserious n=449 · ♀ 100% (drug 79%) · 95% cliniciannot reported in cached trials
Duodenal ulcer perforation3,612682.0
652.3–713.2ROR 774.9 · calibrated p 5e-16 ✓
341.9 EB05 332.7 · IC025 +8.3
3/3 methods agree
Not in label — unassessedserious PRR 252.1 · ♀ 100% (drug 79%) · 94% cliniciannot reported in cached trials
Cardiospasm258604.2
511.3–714.0ROR 609.4 · calibrated p 1e-14 ✓
314.3 EB05 283.4 · IC025 +7.4
3/3 methods agree
Not in label — unassessedserious n=258 · ♀ 54% (drug 79%)not reported in cached trials
Adjustment disorder with depressed mood871534.1
489.2–583.2ROR 550.0 · calibrated p 2e-14 ✓
298.8 EB05 282.5 · IC025 +7.9
3/3 methods agree
Not in label — unassessedserious n=870 · ♀ 100% (drug 79%) · 96% cliniciannot reported in cached trials
Hand deformity5,567520.0
503.2–537.4ROR 637.7 · calibrated p 4e-15 ✓
296.0 EB05 289.5 · IC025 +8.1
3/3 methods agree
Not in label — unassessedserious PRR 237.4 · ♀ 100% (drug 79%) · 93% cliniciannot reported in cached trials
Immunisation173465.5
383.9–564.5ROR 468.2 · calibrated p 2e-13 ✓
269.5 EB05 237.4 · IC025 +7.0
3/3 methods agree
Not in label — unassessedserious n=173not reported in cached trials
Facet joint syndrome1,253462.5
430.9–496.4ROR 482.5 · calibrated p 9e-14 ✓
275.5 EB05 263.0 · IC025 +7.9
3/3 methods agree
Not in label — unassessedserious n=1,253 · ♀ 100% (drug 79%) · 95% cliniciannot reported in cached trials
Dislocation of vertebra859440.9
405.0–480.0ROR 453.8 · calibrated p 2e-13 ✓
267.2 EB05 252.5 · IC025 +7.7
3/3 methods agree
Not in label — unassessedserious n=859 · ♀ 100% (drug 79%) · 95% cliniciannot reported in cached trials
X-ray abnormal666417.0
378.9–458.8ROR 426.4 · calibrated p 3e-13 ✓
257.8 EB05 241.8 · IC025 +7.6
3/3 methods agree
Lab value / disease markerserious n=666 · ♀ 100% (drug 79%) · 97% cliniciannot reported in cached trials
Anticipatory anxiety98397.9
310.3–510.2ROR 399.2 · calibrated p 1e-12 ✓
240.4 EB05 203.1 · IC025 +6.5
3/3 methods agree
Not in label — unassessedserious n=98 · ♀ 100% (drug 79%)not reported in cached trials
Palmoplantar keratoderma252376.7
323.2–439.1ROR 379.9 · calibrated p 1e-12 ✓
239.2 EB05 215.4 · IC025 +7.2
3/3 methods agree
Not in label — unassessedserious n=252 · ♀ 55% (drug 79%)not reported in cached trials
Helicobacter infection3,561375.9
361.4–390.9ROR 426.1 · calibrated p 3e-13 ✓
242.9 EB05 236.3 · IC025 +7.8
3/3 methods agree
Not in label — unassessedserious PRR 189.3 · ♀ 100% (drug 79%) · 94% cliniciannot reported in cached trials
Subcutaneous drug absorption impaired184356.7
298.6–426.1ROR 358.9 · calibrated p 2e-12 ✓
229.4 EB05 202.9 · IC025 +6.9
3/3 methods agree
Not in label — unassessedserious n=184 · ♀ 100% (drug 79%) · 100% cliniciannot reported in cached trials
Retinitis559352.2
318.3–389.8ROR 358.9 · calibrated p 2e-12 ✓
231.3 EB05 215.6 · IC025 +7.5
3/3 methods agree
Not in label — unassessedserious n=559 · ♀ 100% (drug 79%) · 96% cliniciannot reported in cached trials
Pericarditis4,875289.1
280.1–298.3ROR 344.7 · calibrated p 2e-12 ✓
203.5 EB05 198.8 · IC025 +7.6
3/3 methods agree
Not in label — unassessedserious PRR 151.3 · 91% cliniciannot reported in cached trials
Sleep disorder due to general medical condition, insomnia type1,864284.8
270.2–300.2ROR 303.5 · calibrated p 9e-12 ✓
201.1 EB05 193.6 · IC025 +7.5
3/3 methods agree
Not in label — unassessedserious n=1,862 · ♀ 100% (drug 79%) · 94% cliniciannot reported in cached trials
Sleep disorder due to general medical condition, hypersomnia type29284.3
184.4–438.2ROR 284.6 · calibrated p 1e-10 ✓
177.9 EB05 129.9 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=29 · ♀ 100% (drug 79%) · 100% cliniciannot reported in cached trials
Vaginal flatulence88282.2
220.2–361.6ROR 283.0 · calibrated p 3e-11 ✓
191.9 EB05 160.6 · IC025 +6.2
3/3 methods agree
Not in label — unassessedserious n=88 · ♀ 100% (drug 79%)not reported in cached trials
Folliculitis2,741252.3
241.9–263.2ROR 277.5 · calibrated p 2e-11 ✓
184.5 EB05 178.8 · IC025 +7.4
3/3 methods agree
Not in label — unassessedserious PRR 160.0 · ♀ 100% (drug 79%) · 95% cliniciannot reported in cached trials
Synovitis4,750249.5
241.9–257.4ROR 296.1 · calibrated p 1e-11 ✓
183.1 EB05 178.8 · IC025 +7.4
3/3 methods agree
Not in label — unassessedserious PRR 141.3 · ♀ 100% (drug 79%) · 93% cliniciannot reported in cached trials
Tender joint count21228.7
139.6–374.8ROR 228.9 · calibrated p 1e-9 ✓
148.8 EB05 102.7 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=21 · ♀ 100% (drug 79%)not reported in cached trials
Peripheral venous disease985228.6
212.9–245.4ROR 236.3 · calibrated p 9e-11 ✓
171.1 EB05 162.4 · IC025 +7.2
3/3 methods agree
Not in label — unassessedserious n=984 · ♀ 100% (drug 79%) · 95% cliniciannot reported in cached trials
Seronegative arthritis268218.9
190.9–251.1ROR 220.9 · calibrated p 2e-10 ✓
164.3 EB05 148.4 · IC025 +6.8
3/3 methods agree
Not in label — unassessedserious n=268 · ♀ 100% (drug 79%) · 94% cliniciannot reported in cached trials
Urticaria thermal34216.0
147.0–317.6ROR 216.3 · calibrated p 8e-10 ✓
150.8 EB05 112.8 · IC025 +5.0
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=34 · ♀ 100% (drug 79%)not reported in cached trials
Alpha tumour necrosis factor increased22212.6
131.8–343.0ROR 212.8 · calibrated p 2e-9 ✓
142.7 EB05 99.3 · IC025 +4.4
3/3 methods agree
Lab value / disease markerserious n=22 · ♀ 0% (drug 79%)not reported in cached trials
Bronchial neoplasm30196.1
130.7–294.1ROR 196.2 · calibrated p 2e-9 ✓
139.3 EB05 102.3 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=30 · ♀ 100% (drug 79%)not reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Liver injury6,55415.415.1–15.8signal
Interstitial lung disease1,2599.28.8–9.8signal
Hyperglycaemia / diabetes3,4106.96.7–7.1signal
Anaphylaxis / angioedema1,1516.46.1–6.8signal
Depression1,8394.64.4–4.8signal
Serious infection4,8484.44.3–4.5signal
Pancreatitis3102.72.4–3.0signal
Thrombocytopenia6782.12.0–2.3raised
Rhabdomyolysis / myopathy2312.01.7–2.3raised
Severe cutaneous reaction1891.81.5–2.0raised
Gi bleeding4551.71.6–1.9raised
Opportunistic infection3391.71.6–1.9raised
Fall / fracture9221.71.6–1.8raised
Arrhythmia / qt4221.51.4–1.7raised
Tendon disorder771.41.1–1.8raised
Hyponatraemia1511.31.1–1.5raised

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Cetirizine Hydrochloride Tablets as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)9,4005.0
4.9–5.1ROR 6.8 · calibrated p 0.106
5.0 EB05 4.9 · IC025 +2.3
3/3 methods agree
Reporting / coding artifactage-adj. PRR 4.7 · serious PRR 8.9not reported in cached trials
Pain8,84610.1
10.0–10.3ROR 13.9 · calibrated p 0.009 ✓
10.0 EB05 9.8 · IC025 +3.3
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 8.5 · serious PRR 11.5NCT01916226: 1/170 (0.6%) on Cetirizine Hydrochloride Tablets
Fatigue (tiredness)8,7497.9
7.8–8.1ROR 10.8 · calibrated p 0.025 ✓
7.8 EB05 7.7 · IC025 +2.9
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 6.6 · serious PRR 10.6NCT01916226: 1/170 (0.6%) on Cetirizine Hydrochloride Tablets
Alopecia (hair loss)7,44827.4
26.8–27.9ROR 36.0 · calibrated p 9e-5 ✓
26.4 EB05 25.9 · IC025 +4.7
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 19.5 · serious PRR 41.3not reported in cached trials
Rheumatoid arthritis7,36048.5
47.5–49.5ROR 63.8 · calibrated p 3e-6 ✓
45.3 EB05 44.5 · IC025 +5.5
3/3 methods agree
Not in label — unassessedage-adj. PRR 35.0 · serious PRR 40.8 · ♀ 100% (drug 79%)not reported in cached trials
Abdominal discomfort7,32931.9
31.3–32.6ROR 41.8 · calibrated p 4e-5 ✓
30.5 EB05 29.9 · IC025 +4.9
3/3 methods agree
Not in label — unassessedage-adj. PRR 23.6 · serious PRR 50.1not reported in cached trials
Systemic lupus erythematosus7,067174.2
170.1–178.3ROR 227.3 · calibrated p 1e-10 ✓
139.1 EB05 136.4 · IC025 +7.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 123.7 · serious PRR 105.2 · ♀ 100% (drug 79%) · 90% cliniciannot reported in cached trials
Pemphigus6,940893.5
863.7–924.2ROR 1,160.8 · calibrated p 4e-18 ✓
388.3 EB05 380.7 · IC025 +8.5
3/3 methods agree
Not in label — unassessedserious PRR 287.3 · ♀ 100% (drug 79%) · 90% cliniciannot reported in cached trials
Off label use (used outside approved label)6,6105.3
5.2–5.5ROR 6.6 · calibrated p 0.118
5.3 EB05 5.2 · IC025 +2.4
3/3 methods agree
Reporting / coding artifactage-adj. PRR 5.2 · serious PRR 6.6not reported in cached trials
Rash6,53610.6
10.4–10.9ROR 13.3 · calibrated p 0.011 ✓
10.5 EB05 10.3 · IC025 +3.4
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 9.3 · serious PRR 16.8not reported in cached trials
Swelling5,99047.7
46.6–48.8ROR 59.3 · calibrated p 4e-6 ✓
44.7 EB05 43.7 · IC025 +5.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 36.3 · serious PRR 53.2 · 91% cliniciannot reported in cached trials
Hypersensitivity (allergic reaction)5,65821.9
21.4–22.4ROR 26.7 · calibrated p 5e-4 ✓
21.3 EB05 20.8 · IC025 +4.4
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 21.3 · serious PRR 29.0not reported in cached trials
Hand deformity5,567520.0
503.2–537.4ROR 637.7 · calibrated p 4e-15 ✓
296.0 EB05 289.5 · IC025 +8.1
3/3 methods agree
Not in label — unassessedserious PRR 237.4 · ♀ 100% (drug 79%) · 93% cliniciannot reported in cached trials
Infusion related reaction (reaction during infusion)5,49463.2
61.6–64.8ROR 77.0 · calibrated p 8e-7 ✓
57.9 EB05 56.6 · IC025 +5.8
3/3 methods agree
Not in label — unassessedage-adj. PRR 48.1 · serious PRR 53.6 · ♀ 99% (drug 79%) · 92% cliniciannot reported in cached trials

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Oxycodone Hydrochloride ↔ Drug Dependence.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Cetirizine Hydrochloride Tablets?

In FDA FAERS, the most frequently co-reported reaction terms for Cetirizine Hydrochloride Tablets are pain, fatigue, alopecia, rheumatoid arthritis, abdominal discomfort, systemic lupus erythematosus. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Cetirizine Hydrochloride Tablets have an FDA boxed warning?

No. The FDA label retrieved for Cetirizine Hydrochloride Tablets has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Cetirizine Hydrochloride Tablets causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.